3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
10
Phase 1/2
3
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Urinary Bladder Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Breast Neoplasms
1
Interventions
umbralisib
1
ublituximab
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Has announcements
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA